World Alzheimer's Day: How to improve the safety, compliance and accessibility of medicines?

Every September 21 is World Alzheimer's Day
.
As one of the biggest global public health and social health challenges facing humanity now and in the future, there is currently no curable or reversible treatment for Alzheimer's disease
.
How to improve the treatment effect of Alzheimer's disease, reduce the side effects of drugs, improve patient compliance, reduce the burden of family care, and increase the accessibility of drugs are problems that the medical community faces urgently to be resolved
.
Alzheimer’s disease: heavy burden of care and high drug withdrawal rate.
With the accelerated aging of our country’s population and the increase in the prevalence of major cardiovascular diseases and related factors, the prevalence of Alzheimer’s disease and The number of patients is also increasing year by year
.
It is predicted that there are more than 10 million Alzheimer's disease (AD) patients in China, accounting for 1/5 of the global number of patients.
The number of patients in my country will reach 21 million by 2050! The prevalence rate in the group over 60 years old is as high as 3.
9%, and the incidence rate in women is higher than that in men
.
Alzheimer's disease is the most common irreversible neurodegenerative disease, from mild to moderate to severe is an extremely long process
.
On the one hand, memory impairment and cognitive abnormality caused by Alzheimer’s disease pose a serious threat to the life and health of the elderly; on the other hand, due to the decline in basic self-care ability, the elderly need long-term, all-weather family care and social care.
Health care services also bring heavy economic and care burdens to families and society
.
According to a domestic survey, 83.
9% of Alzheimer's disease patients are taken care of by their spouses, 10.
7% are taken care of by their children, and 5.
4% are taken care of by nanny or caregiver
.
Approximately 57% of the caregivers are accompanied throughout the day, and nearly two-thirds of the caregivers say they feel a light or more burden
.
Early intervention is essential to improve or delay the development of Alzheimer's disease
.
However, in clinical diagnosis and treatment practice, due to lack of understanding, stigma, patient disability, dementia, etc.
, late treatment, low treatment rate, high drug withdrawal rate, poor treatment compliance, and often fail to obtain the best results
.
A safe and effective treatment plan can significantly improve the condition, reduce the burden of care, and improve the quality of life of patients and their families, thereby reducing the burden of disease
.
A considerable number of patients with Alzheimer's disease have a strong sense of rejection of medication
.
In addition, the "Survey Report on the Diagnosis and Treatment Status of Alzheimer's Disease Patients in China" released for the first time in 2021 showed that more than 70% of the patients who have received treatment stopped the drug within 3 years.
In addition to price factors, the reasons include poor efficacy (63.
79).
%) and more side effects (34.
74%)
.
Patients in remote areas are particularly difficult to administer drugs and do not cooperate with treatment
.
Transdermal Patches: Improve the safety and compliance of Alzheimer's disease medications Dosage form
.
Among them, transdermal patch is one of the important research directions
.
Compared with oral preparations, transdermal patches have a larger drug load, which helps delay the development of Alzheimer's disease and relieve symptoms
.
The transdermal patch is easy to use, has less gastrointestinal side effects, better protects the liver and kidneys, and can better help those with dysphagia, oral drug intolerance, liver and kidney damage, combined diseases, and digestive tract Patients with medical history, psychiatric symptoms who do not cooperate with medication, and groups of patients who need to use large doses
.
Listigmine is currently the first-line medication for the treatment of mild to moderate Alzheimer's disease and has been recommended by authoritative guidelines in many countries
.
Kingsmin changes the route of administration and is administered through the skin, allowing the drug to be absorbed from the blood vessels in the dermis through the epidermis into the systemic blood circulation to reach an effective blood drug concentration, which can significantly improve the cognitive function and overall function of Alzheimer's disease patients, and The curative effect is equivalent to the oral preparation of Listigmine
.
Compared with oral preparations, Kingsmin has better safety and compliance
.
In terms of safety, Lismin's transdermal patch is neither metabolized by the liver CYP450 enzyme, nor does it increase the burden on the kidneys; it can reduce systemic adverse events, especially gastrointestinal-related adverse reactions
.
In terms of tolerability, Lissmin transdermal patch provides stable, continuous administration and long-lasting therapeutic plasma drug concentration, which is easier to titrate to the target dose, which enables patients to start high-dose medication as soon as possible, which helps to delay The course of the disease develops
.
At the same time, the once-a-day patch administration is more convenient, which can not only improve the patient's medication compliance, but also reduce the caregiver's medication management time and reduce the burden on the patient's family
.
Jin Siming (one post per day) has been officially supplied to hospitals and pharmacies across the country after the first prescription was issued at the Mental Health Center of Zhejiang University School of Medicine in January 2021
.
At the same time, King Siming (one post per day) is also online on the large e-commerce platform JD.
com
.
With the introduction of favorable policies such as the inclusion of Internet medical insurance and the conditional opening of online purchase of prescription drugs, the availability of Alzheimer’s medicines has greatly improved.
Be effectively improved
.